Business
Capricor Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before September 15, 2025 to Discuss Your Rights - CAPR
NEW YORK - September 2, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in ...
About this update from Caprock Mining Corp
[{"type":"text","content":"Capricor Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before September 15, 2025 to Discuss Your Rights - CAPRNEW YORK - September 2, 2025 (NEWMEDIAWIRE) - Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of a class action securities lawsuit.\n\nCLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Capricor investors who were adversely affected by alleged securities fraud between October 9, 2024 and July 10, 2025. Follow the link below to get more information and be contacted by a member of our team:\nhttps://zlk.com/pslra-1/capricor-therapeutics-inc-lawsuit-submission-form-2?prid=164198&wire=56\nCAPR investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.\nCASE DETAILS: According to the complaint, defendants provided investors with material information concerning Capricor’s lead cell therapy candidate drug deramiocel for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Defendants’ statements included, among other things, Capricor’s ability to obtain a Biologics License Application (BLA) for deramiocel from the U.S. Food and Drug Administration (FDA). Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning its four-year safety and efficacy data from its Phase 2 HOPE-2 trial study of deramiocel.   On July 11, 2025, Capricor issued a press release announcing it received a Complete Response Letter (CRL) from the FDA denying the BLA specifically citing it did not meet the statutory requirement for substantial evidence of effectiveness and the need for additional clinical data. Further, the CRL referenced outstanding items in the Chemistry, Manufacturing, and Controls section of the application.   Following this news, the price of Capricor stock declined from $11.40 per share on July 10, 2025 to $7.64 per share on July 11, 2025.\nWHAT'S NEXT? If you suffered a loss in Capricor during the relevant time frame, you have until September 15, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require t...